News BMS gets FDA OK for first LAG-3 checkpoint inhibitor Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co.
News Clinical trial go-between Inato raises $20m Inato has raised $20 million in early-stage financing to support the continued development of its clinical trial marketplace, which connects sponsors with its network of t
R&D Sponsored Trials and tribulations of drug development What does it take to establish new treatments for rare diseases?